Top Story Today
Roche Writes a $700 Million Check to Blow Up Proteins (Literally)
Most drugs block disease-causing proteins like putting a boot on a car. Roche just bet $700 million upfront (up to $2.3 billion total) on a drug that calls the tow truck instead. Nurix's bexobrutideg hijacks the cell's recycling system to physically destroy BTK, a protein that drives blood cancers. Early data showed an 83% response rate in heavily pretreated CLL patients, including those carrying mutations that defeat every existing BTK inhibitor. Nurix stock surged over 40%, and the 50/50 U.S. profit split means this isn't a licensing deal; it's a co-ownership bet on the most lucrative market on Earth.
Why it matters: This is one of the largest targeted protein degradation deals ever struck, and the fact that it's built around a specific late-stage drug (not just a discovery platform) signals that Big Pharma now views degraders as a registrational-stage modality, not a science project.
Read more →Deals and M&A
Incyte Drops $2 Billion on a Disease You've Probably Never Heard Of
With Jakafi generating 67% of revenue and its patents expiring in December 2028, Incyte made its biggest acquisition ever: $1.25 billion upfront (plus $750 million in milestones) for Vega Therapeutics and its Phase 3 antibody targeting von Willebrand disease, the most common inherited bleeding disorder. It's the boldest move yet in Incyte's race to build a post-Jakafi identity.
Read more →Lilly Paid $202 Million for a Company With No Drug
Eli Lilly acquired Engage Biologics, a seed-stage Y Combinator graduate with no clinical trials, for up to $202 million. The prize: a preclinical "Tethosome" platform that claims to boost non-viral DNA delivery over 100-fold by smuggling genetic payloads past the cell membrane and into the nucleus. It's the latest piece of Lilly's genetic medicines shopping spree, which now exceeds $13 billion.
Read more →GSK Bets 44 Million Pounds That Scar Tissue Can Be Reversed
GSK signed a research collaboration with London-based Engitix to hunt for drug targets that actively reverse liver fibrosis, not just slow it down. The deal is worth up to 44.5 million pounds in upfront and near-term payments, with milestones reaching 118 million per target. It's the latest addition to GSK's quiet fibrosis empire, which already includes a $1.2 billion bet on a Phase 3 liver disease drug.
Read more →The Obesity Wars
Boehringer's Obesity Drug Just Ran Into a Wall Called Tirzepatide
Full ADA 2026 data for Boehringer's survodutide showed 16.6% weight loss at the highest dose, solid in isolation but well below tirzepatide's 21%. Worse, roughly 19-20% of patients dropped out due to GI side effects. Zealand Pharma (Boehringer's public partner) cratered 25% in a day. The potential silver lining: survodutide cut liver fat by 63%, which could carve out a niche if the obesity market starts valuing organ-specific outcomes.
Read more →A Tiny Danish Biotech Is Betting Against the Hottest Strategy in Medicine
While the entire industry races to activate the GIP receptor (the strategy behind Lilly's tirzepatide), Antag Therapeutics showed up at ADA 2026 with Phase 1 data proving you can safely block it instead. Their drug AT7687, backed by an 80 million euro Series A, is headed to Phase 2a. In preclinical combos with a GLP-1 drug, insulin dropped 52% and LDL cholesterol plunged 48%.
Read more →Clinical Milestones
CAR-T Just Broke Into the Solid Tumor Club
Shanghai's OriCell Therapeutics got China's NMPA to clear the first-ever randomized, registration-intent CAR-T trial in liver cancer. The Phase 1b data that got them there: a 50% response rate (66.7% at the recommended dose) in patients who had exhausted all other options. No CAR-T has ever been approved for a solid tumor anywhere in the world, making this a potential watershed for the entire field.
Read more →